Phase 1 Study of KHK2898 in Subjects With Advanced Solid Tumors
Phase 1, Open-Label, Dose Escalation Study of Anti-CD98 Monoclonal Antibody KHK2898 as Monotherapy in Subjects With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or For Whom No Standard Therapy Is Available
Sponsor: Kyowa Kirin Co., Ltd.
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Kyowa Kirin Co., Ltd.
- Apathy · Dec 2023
- Diabetic Kidney Disease · Phase PHASE3 · Jul 2023
- Follicular Lymphoma (FL) · Phase PHASE3 · Mar 2023
- Urothelial Carcinoma · Phase PHASE1 · Nov 2022
- Healthy Volunteers · Phase PHASE1 · Aug 2022
More terminations from Kyowa Kirin Co., Ltd.
Other Solid Tumour trials with similar outcome
A PHASE1 clinical study on Solid Tumour, this trial is terminated or withdrawn. The trial is conducted by Kyowa Kirin Co., Ltd. and has accumulated 8 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Aug 2019 — Jan 2021 [monthly]
Terminated PHASE1
-
Jun 2018 — Aug 2019 [monthly]
Terminated PHASE1
▶ Show 3 earlier versions
-
Apr 2017 — Jun 2018 [monthly]
Terminated PHASE1
Status: Not Yet Recruiting → Terminated
-
Feb 2017 — Apr 2017 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Jan 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kyowa Kirin Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .